波士顿科学任命菲茨杰拉德为首席运营官，明年起拆分三大业务板块
总部位于马萨诸塞州马尔伯勒的医疗器械巨头波士顿科学公司（Boston Scientific）10月12日宣布，任命约瑟夫·M·菲茨杰拉德（Joseph M. Fitzgerald）为执行副总裁兼首席运营官，2027年1月1日起生效。他将全面负责公司全球运营、业务单元和各区域事务。与此同时，公司宣布将从2027年1月1日起设立三个新的报告板块：介入治疗（Interventional Therapies）、心律解决方案（Rhythm Solutions）和医疗外科（MedSurg）。公司表示，这一架构旨在加快决策速度、优化投资配置。菲茨杰拉德目前担任公司心血管业务集团总裁，此次升任后，三个板块的负责人将直接向他汇报。
据公司财报电话会披露，波士顿科学2026年第二季度营收54.4亿美元，同比增长7.5%；调整后每股收益0.86美元，同比增长15%。管理层预计第三季度有机营收增长3%至5%。今年1月公司还宣布了对Penumbra的收购协议，交易完成后该业务将并入介入治疗板块。这次高层与架构的双重调整，被视为公司在医疗器械赛道加速扩张的信号。
Boston Scientific Names Fitzgerald COO, to Split Into Three Segments Next Year
Boston Scientific, the medical device giant headquartered in Marlborough, Massachusetts, announced on October 12 that Joseph M. Fitzgerald has been named executive vice president and chief operating officer, effective January 1, 2027. He will oversee the company's global operations, business units and regions. At the same time, the company said it will reorganize into three new reporting segments starting January 1, 2027: Interventional Therapies, Rhythm Solutions and MedSurg. The company said the structure is designed to speed decision-making and optimize investment allocation. Fitzgerald currently serves as group president of the company's cardiovascular business; after his promotion, the heads of the three segments will report directly to him.
According to the company's earnings call, Boston Scientific posted second-quarter 2026 revenue of $5.44 billion, up 7.5% year over year, with adjusted earnings per share of $0.86, up 15%. Management guided third-quarter organic revenue growth of 3% to 5%. In January, the company also announced an agreement to acquire Penumbra; once completed, that business will be folded into the Interventional Therapies segment. The combined leadership and structural overhaul is seen as a signal that the company is accelerating its expansion in the medical device arena.
图片来源：图：波士顿科学总部所在地马尔伯勒市主街实景（资料图）。摄影：John Phelan，CC BY 3.0，来源：Wikimedia Commons
